Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis

1 Jun 2020

Abstract excerpt

Background: MET amplifications occur in human tumors, including non-small cell lung cancer (NSCLC). MET inhibitors have demonstrated some clinical activity in MET amplified NSCLC, presumably with a gene dose effect. However, the definition of MET positivity or MET amplification as a potential oncogenic driver is still under debate. In this study, we aimed to establish the molecular subgroup of NSCLC with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32676323
DOI: 10.21037/tlcr-19-339

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosisPMID 32676323Read ↗

MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLCSemantic proximity Read ↗

Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogiesSemantic proximity Read ↗

Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification.Semantic proximity Read ↗

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitorsSemantic proximity Read ↗

High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.Semantic proximity Read ↗

<i>MET</i> Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the LungSemantic proximity Read ↗

MET Amplification in Non-Small Cell Lung Cancer (NSCLC)—A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World SettingSemantic proximity Read ↗

The METeoric rise of MET in lung cancerSemantic proximity Read ↗

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)Semantic proximity Read ↗

Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.Semantic proximity Read ↗

Clinical Implications of <i>MET</i> Gene Copy Number in Lung CancerSemantic proximity Read ↗

Copy number gain of MET gene with low level in a metastatic lung adenocarcinoma patient represents response to salvage treatment with savolitinib and osimertinib: a case reportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.